// App-Quantinova.ai

3047 : Anti-PD-1 monoclonal antibody combined CD3-retronectin activated T cell in heavy-treated renal cell cancer.

Researchers

Presenter

  • Lingdi Zhao

Principal Investigators

  • Wei Li

  • Yonghao Yang

  • Yong Zhang

  • Xiubao Ren

  • Quanli Gao

Medical Centers

  • Cancer Hospital affiliated to Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China

  • Tianjin Medical University Cancer Hospital, Tianjin, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Nephrology

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • RetroNectin

  • Nivolumab

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved